UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary shares, nominal value $0.0001 per share JAZZ The Nasdaq Stock Market LLC Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 or ☐ Transition report pursuant to Section 1 ...

| --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------|-------|-------|-------|-------|----------| | | | | | | | | | | | | | | | | | | | | | | 2024 Second Quarter | | | | | | | Innovating to Transform the Lives of Patients and Their Families Financial Results | | | | | | | | | | | | | | | | | | | Caroline | Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-lookin ...

Jazz Pharmaceuticals plc. (NASDAQ:JAZZ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Andrea Flynn - Vice President and Head-Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Renée Galá - President and Chief Operating Officer Rob Iannone - Executive Vice President and Global Head-R&D Phil Johnson - Executive Vice President and Chief Financial Officer Conference Call Participants Jason Gerberry - Bank of America Marc Goodman - Leerink Jessica Fye - JPMorg ...

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $5.30 per share, beating the Zacks Consensus Estimate of $4.68 per share. This compares to earnings of $4.51 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 13.25%. A quarter ago, it was expected that this drugmaker would post earnings of $4.14 per share when it actually produced earnings of $2.68, delivering a surprise of -35.27%. Over the last four quarters, th ...

Exhibit 99.1 Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance – 15% year-over-year revenue increase from combined key growth drivers: Xywav , Epidiolex and Rylaze – – Oncology revenues grew 10% year-over-year – – Zanidatamab granted Priority Review by U.S. FDA for 2L BTC; PDUFA date of November 29, 2024 – – Near-term, late-stage pipeline catalysts anticipated through 2025 – – Narrowing 2024 total revenue guidance to $4.0 to $4.1 billion – – Affirming G ...

– 15% year-over-year revenue increase from combined key growth drivers: Xywav®, Epidiolex® and Rylaze® – – Oncology revenues grew 10% year-over-year – – Zanidatamab granted Priority Review by U.S. FDA for 2L BTC; PDUFA date of November 29, 2024 – – Near-term, late-stage pipeline catalysts anticipated through 2025 – – Narrowing 2024 total revenue guidance to $4.0 to $4.1 billion – – Affirming GAAP and non-GAAP adjusted net income guidance – DUBLIN, July 31, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasd ...

The biotechnology sector doesn't need to rizz up investors, as the kids like to say. Unless the human desire to find solutions for vexing conditions and diseases somehow goes away in a dystopian paradigm, the ecosystem is safe. I'd venture to say that it's permanently relevant. However, that doesn't necessarily mean you should buy any example of biotech stocks that come your way. However, the sector faces significant risks – it's not the most predictable industry. One bad clinical result can send enterprise ...

This Earnings ESP, combined with its Zacks Rank #4 (Sell), makes it difficult to conclusively predict that Stevanato will beat the consensus EPS estimate. Over the last four quarters, the company surpassed EPS estimates just once. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Jazz doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. ...

Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing por ...

DUBLIN, July 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 second quarter financial results on Wednesday, July 31, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2024 second quarter financial results and provide a business and financial update. Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceutica ...